Processa Pharmaceuticals Inc (NAS:PCSA)
$ 1.19 -0.12 (-9.16%) Market Cap: 3.88 Mil Enterprise Value: -1.58 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 30/100

Q4 2022 Processa Pharmaceuticals Inc Earnings Call Transcript

Mar 30, 2023 / 08:30PM GMT
Release Date Price: $9.6 (+5.63%)
Operator

Greetings and welcome to the Processa Pharmaceuticals year-end 2022 earnings call and corporate update. (Operator Instructions) As a reminder, this call is being recorded. It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. Thank you, sir. You may begin.

Jim Stanker
Processa Pharmaceuticals, Inc. - CFO

Thank you, and welcome to Processa's 2022 year-end results and corporate update conference call. Joining me on the call today is our Chief Executive Officer, Dr. David Young.

Shortly before this call, we filed our year-end Form 10-K. I will briefly touch on our published financial results, and then turn it over to Dr. Young to provide an update on our drug development activities. I want to remind everyone that a PowerPoint presentation will accompany Dr. Young's prepared remarks. To view the PowerPoint presentation, please go to the Investor Relations section on our website or to our earnings press release and click the webcast link to follow along.

I'll start by reading the Safe Harbor statement. This statement is made

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot